terlipressin has been researched along with Hepatorenal Syndrome in 216 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (1.39) | 18.2507 |
| 2000's | 56 (25.93) | 29.6817 |
| 2010's | 96 (44.44) | 24.3611 |
| 2020's | 61 (28.24) | 2.80 |
| Authors | Studies |
|---|---|
| Karasu, Z; Ustundag, Y; Yilmaz Urun, Y | 1 |
| Allegretti, AS; Belcher, JM; Chung, RT; Garcia-Tsao, G; Juncos, LA; Karakala, N; Nadim, MK; Parada, XV; Parikh, SM; Regner, KR; Sharma, P; Simonetto, DA; Velez, JCQ; Wadei, HM | 1 |
| Leary, PJ; Paine, CH; Pichler, RH; Swenson, ER | 1 |
| Gonzalez, SA; Velez, JCQ | 1 |
| Gupta, R; Kulkarni, AV; Kumar, K; Premkumar, M; Rao, PN; Ravikumar, ST; Reddy, DN; Sharma, M; Tevethia, H | 1 |
| Velez, JCQ | 1 |
| Buccheri, S; Da, BL | 1 |
| Andraus, W; Arantes, RM; Carneiro-D'albuquerque, LA; Cunha, MR; De Moura, EG; Ducatti, L; Ernani, L; Fernandes, MR; Galvão, FH; Martino, RB; Nacif, LS; Pereira, PB; Pinheiro, RS; Rocha-Santos, V; Waisberg, DR | 1 |
| Alhazzani, W; Bagshaw, SM; Dionne, JC; Helmeczi, W; Kiflen, M; Needham-Nethercott, N; Pitre, T; Rewa, O; Rochwerg, B; Zeraatkar, D | 1 |
| Allegretti, AS; Cárdenas, A; Francoz, C; Olson, JC; Subramanian, RM | 1 |
| Curry, MP; Jamil, K; Pappas, SC; Reddy, KR; Sanyal, A; Vargas, H; Wong, F | 1 |
| Jalan, R; Singal, AK | 1 |
| Befeler, AS; Curry, MP; Jamil, K; Patwardhan, VR; Pyrsopoulos, NT; Vargas, HE | 1 |
| Kwo, P; Wong, F | 1 |
| Aschenbrenner, DS | 1 |
| Allegretti, AS; Belcher, JM; Kanduri, SR; Karakala, N; Kovacic, RA; Mohamed, MMB; Regner, KR; Tayebi, K; Therapondos, G; Velez, JCQ; Wentowski, C; Wickman, TJ | 1 |
| Frederick, RT; Jamil, K; Pappas, SC; Sanyal, AJ; Sigal, SH; Weinberg, EM | 1 |
| Aschenbach, R; Franken, P; Platzer, S; Ripoll, C; Schuhmacher, U; Stallmach, A; Steighardt, J; Teichgräber, U; Wienke, A; Zipprich, A | 1 |
| Agrawal, D; Ariga, KK; Verma, G | 1 |
| Curry, MP; Gonzalez, SA; Jamil, K; Pappas, SC; Reddy, KR; Sanyal, AJ; Vargas, HE; Velez, JCQ; Wong, F | 1 |
| Chandel, S; De, A; Jayachandran, A; Sharma, N; Singh, A; Singh, V | 1 |
| Parikh, ND; Tapper, EB | 1 |
| Belcher, JM | 2 |
| Cao, J; Gow, P; Lim, PCH; Sinclair, M; Terbah, R; Testro, A; Wong, D | 1 |
| Bajaj, JS; Duong, N; Kakadiya, P | 1 |
| Bindra, J; Chopra, I; Huang, X; Niewoehner, J; Wan, GJ | 1 |
| Bass, SN; Kapoor, A; Lindenmeyer, CC | 1 |
| Christaki, M; Despotis, G; Kalambokis, GN; Milionis, HJ; Tsiakas, I | 1 |
| Lok, AS; Sharma, P; Tapper, EB; Taylor, A; Thomson, MJ | 1 |
| Beldi, G; Candinas, D; De Gottardi, A; Kohler, A; Perrodin, S | 1 |
| Mohanty, A | 1 |
| Liu, CH; Wang, J; Xing, F | 1 |
| Allegretti, AS; Bakker, R; Corman, S; Heisen, M; Huang, X; Jamil, K; Kebede, N; Leonardi, R; Luo, L; Maï, C; Moore, K; Shamseddine, N; Verleger, K | 1 |
| Gow, P; Sinclair, M; Terbah, R; Testro, A | 1 |
| Brown, RS; Ganger, D; Grewal, P; Moore, K; Sharma, P | 1 |
| Dev, D; Krishna, R; Prasad, SC; Raj, J; Reghu, R; V, SO | 1 |
| Anand, A; Deep, A; Saxena, R | 1 |
| Aithal, GP; Palaniyappan, N | 1 |
| Allegretti, AS; Jamil, K; Moore, K | 3 |
| Angeli, P; Boccagni, P; Burra, P; Calvino, V; Cillo, U; Gambino, C; Germani, G; Gringeri, E; Piano, S; Tonon, M; Vettore, E | 1 |
| Angus, PW; Chapman, B; Gow, PJ; Sinclair, M; Terbah, R; Testro, AG; Thwaites, PA | 1 |
| Arab, JP; Benítez, C; Kulkarni, AV; Kumar, P; Premkumar, M; Rao, PN; Reddy, DN; Sharma, M; Simonetto, DA; Tirumalige Ravikumar, S | 1 |
| Ardila, G; De la Hoz-Valle, JA; De Zubiria, A; Delgado, AF; Pérez-Riveros, ED; Pinto, R; Rey R, M; Sierra-Arango, F | 1 |
| De, A; Mehtani, R; Singh, V | 1 |
| Busta Nistal, MR; Fernández Salazar, L; Mora Cuadrado, N | 1 |
| Beaman, J; Bui, TNN; Czarniak, P; Luna, G; Sandar, S; Sunderland, B | 1 |
| Curry, MP; Escalante, S; Frederick, RT; Gonzalez, SA; Jamil, K; Lim, N; Mayo, MJ; Mumtaz, K; Pappas, SC; Porayko, MK; Reddy, KR; Rubin, RA; Sanyal, AJ; Sharma, P; Simonetto, DA; Wong, F | 1 |
| Balbinot, RA; Balbinot, RS; Balbinot, SS; Balensiefer, JIL; Cini, BT; Eberhardt, LZ; Longen, ML; Luis Rost, G; Muscope, ALF; Schena, B; Soldera, J; Terres, AZ | 1 |
| Andria, I; Surace, M; Valentini, G | 1 |
| Brown, K; Brown, RS; Burra, P; Flamm, SL; Kugelmas, M; Poordad, F; Saab, S; Samaniego-Picota, M; Wadei, HM | 1 |
| Moret-Bochatay, M | 1 |
| Biggins, SW; Evans, L; Paine, CH; Pichler, RH | 1 |
| Lindenmeyer, CC; Sundaram, V; Vipani, A | 1 |
| Jagdish, RK; Jindal, A | 1 |
| Gadano, A; Garcia-Olveira, L; Mauro, E | 1 |
| Weng, F | 1 |
| Francoz, C; Khemichian, S; Nadim, MK | 1 |
| Araya, V; Boyer, TD; Escalante, S; Frederick, RT; Jamil, K; Pappas, SC; Reddy, KR; Rossaro, L; Sanyal, AJ; Teuber, P; Vargas, HE; Wong, F | 1 |
| Ginès, P | 3 |
| Chandar, AK; Facciorusso, A; Kamath, PS; Murad, MH; Muscatiello, N; Prokop, LJ; Singh, S | 1 |
| Fallowfield, JA; Gifford, FJ | 1 |
| Braddock, M; Han, YJ; Sun, DQ; Zheng, JN; Zheng, MH; Zhong, JH; Zhou, YJ; Zou, TT | 1 |
| Golestaneh, L; Neugarten, J | 1 |
| Angeli, P; Piano, S; Tonon, M | 1 |
| Allegretti, AS; Gluud, LL; Goldin, AH; Israelsen, M; Jovani, M; Krag, A; Winter, RW | 1 |
| Nanda, A; Reddy, R; Safraz, H; Salameh, H; Singal, AK | 1 |
| Durand, F; Nadim, MK; Olson, JC | 1 |
| Baltayiannis, G; Christodoulou, D; Christou, L; Kalambokis, GN | 1 |
| Colle, I; Laterre, PF | 1 |
| Alessandria, C; Amoros, A; Angeli, P; Ariza, X; Arroyo, V; Bernardi, M; Gerbes, A; Gines, P; Gustot, T; Hüsing-Kabar, A; Maschmeier, M; Nevens, F; Piano, S; Romano, A; Scheiner, B; Schmidt, HH; Solà, E; Solè, C; Tonon, M; Trebicka, J | 1 |
| Baltayiannis, G; Christaki, M; Christodoulou, D; Christou, L; Kalambokis, GN; Koustousi, C; Tsiakas, I | 1 |
| Mindikoglu, AL; Pappas, SC | 1 |
| Bo, W; Feng, X; Hu, Y; Liu, A; Wang, H | 1 |
| Reiberger, T | 1 |
| Satsangi, S | 2 |
| Allegretti, AS; Gluud, LL; Goldin, AH; Israelsen, M; Jovani, M; Krag, A; Schulman, AR; Winter, RW | 1 |
| Andrabi, MS; Dar, HA; Javid, G; Saif, RU; Sofi, SM; Zargar, SA | 1 |
| Angeli, P; Ginès, P; Kamath, PS; Nadim, MK; Solà, E; Wong, F | 1 |
| Borg, K; Lange, LB | 1 |
| Deng, J; Liu, L; Qi, X; Rössle, M; Zhang, J; Zhou, X | 1 |
| Carol, M; Cereijo, U; dePrada, G; Fabrellas, N; Farrés, J; Ginès, P; Graupera, I; Huelin, P; Jiménez, W; Juanola, A; Mas, JM; Morales-Ruiz, M; Moreira, R; Napoleone, L; Pose, E; Solà, E; Solé, C; Torres, F | 1 |
| Chiang, CW; Huang, YB; Lin, YJ | 1 |
| Boyer, TD; Escalante, S; Jamil, K; Pappas, SC; Sanyal, AJ; Wong, F | 1 |
| Galle, PR; Jäger, J; Labenz, C; Marquardt, JU; Nagel, M; Nguyen-Tat, M; Rey, JW; Wörns, MA | 1 |
| Ahmed, R; Haseeb, A | 1 |
| Hsu, SJ; Huang, HC | 1 |
| Agarwal, R; Bhalla, A; Chawla, YK; Choudhary, NS; Ghosh, S; Kumar, P; Sharma, AK; Sharma, N; Singh, B; Singh, V | 1 |
| Cárdenas, A; Ginès, P; Solà, E | 1 |
| Bendtsen, F; Egerod Israelsen, M; Gluud, LL; Krag, AA; Møller, S | 1 |
| Aytan, P; Erdemır, F; Kisacik, B; Köseoğlu, RD; Kutlutürk, F; Taşliyurt, T; Yelken, BM; Yilmaz, A | 1 |
| Blokhina, NV; Pasechnik, IN | 1 |
| Alessandria, C; Andrealli, A; Arroyo, V; Barreto, R; Elia, C; Fernández, J; Ginès, P; Graupera, I; Guevara, M; Pereira, G; Poca, M; Rodríguez, E; Sánchez, J; Solà, E; Soriano, G | 1 |
| Choi, JH; Choung, RS; Hyun, JJ; Jung, SW; Kim, HR; Koo, JS; Lee, HJ; Lee, SJ; Lee, SW; Lee, YS; Ryu, JY; Yim, HJ; Yoon, EL | 1 |
| Durand, F; Francoz, C | 1 |
| Garrett, K; Gow, P; Majumdar, A; Robertson, M; Rumler, G; Testro, A | 1 |
| Egerod Israelsen, M; Gluud, LL; Krag, A | 1 |
| Peng, J; Wan, S; Wan, X; Zhu, Q | 1 |
| Carrilho, FJ; D' Albuquerque, LA; Farias, AQ; Malbouisson, LM; Nassar Junior, AP | 1 |
| Elia, C; Ginès, P; Rodríguez, E; Solà Vergés, E | 1 |
| Bailey, M; Bellomo, R; Eastwood, GM; Goodwin, MD; Schelleman, A; Schneider, AG | 1 |
| Ahrens, J; Galle, PR; Götz, E; Marquardt, JU; Nguyen-Tat, M; Rey, JW; Schattenberg, J; Scholz-Kreisel, P; Sivanathan, V; Wörns, MA | 1 |
| Angeli, P; Bernardi, M; Caraceni, P; Cavallin, M; Colletta, C; Di Giacomo, A; Fasolato, S; Fornasiere, E; Gatta, A; Kamath, PS; Merli, M; Morando, F; Piano, S; Ridola, L; Romanelli, RG; Salerno, F; Salinas, F; Toniutto, P | 1 |
| Janicko, M; Jarcuska, P; Senajova, G; Veseliny, E | 1 |
| Angeli, P; Cavallin, M; Fasolato, S; Marenco, S; Piano, S; Tonon, M | 1 |
| Debernardi Venon, W; Marzano, A; Rizzetto, M; Sacco, M | 1 |
| Arroyo, V; Barreto, R; Colmenero, J; Elia, C; Fernandez, J; Ginès, P; Henrique Pereira, G; Navasa, M; Pose, E; Rodriguez, E; Solà, E | 1 |
| Celis, P; Rada, G | 1 |
| Angus, P; Ardalan, Z; Gow, P; Testro, A; Vasudevan, A | 1 |
| Mattos, AA; Mattos, ÂZ; Ribeiro, RA | 1 |
| Angeli, P; Benetti, G; Cavallin, M; Cillo, U; Fasolato, S; Frigo, AC; Gola, E; Morando, F; Piano, S; Romano, A; Rosi, S; Stanco, M; Sticca, A | 1 |
| Boyer, TD; Frederick, RT; Ganger, D; Jamil, K; Lake, JR; O'Leary, JG; Pappas, SC; Sanyal, AJ; Wong, F | 1 |
| Edrees, AM; El-Abd, OL; El-Azab, GI; El-Said, HH; Salman, TA | 1 |
| Buder, R; Lenz, K; Lohr, G; Piringer, P; Voglmayr, M | 1 |
| Bertino, G; Crisafulli, E; Demma, S; Koukias, N; Privitera, G; Purrello, F; Spadaro, L; Tsochatzis, EA | 1 |
| Bajaj, JS; Boyer, TD; Escalante, S; Jamil, K; Pappas, SC; Sanyal, AJ; Wong, F | 1 |
| Charrabi, A; Colson, PH; Corbani, M; Gaudard, P; Guillon, G; Manière, MJ; Richard, S; Virsolvy, A | 1 |
| Goyal, O; Puri, S; Sehgal, N; Sidhu, SS | 1 |
| Fallowfield, JA; Gifford, FJ; Morling, JR | 1 |
| Kumar, A; Sarin, SK; Sharma, P; Shrama, BC | 1 |
| Kalambokis, GN; Tsianos, EV | 1 |
| Döhler, KD; Meyer, M | 1 |
| Bendtsen, F; Holstein-Rathlou, NH; Krag, A; Møller, S; Pedersen, EB | 1 |
| Bendtsen, F; Borup, T; Krag, A; Møller, S | 1 |
| Broelsch, CE; Canbay, A; Gerken, G; Saner, FH | 1 |
| Denzer, UW; Geibler, M; Glowa, F; Lohse, AW; von Kalckreuth, V | 1 |
| Alessandria, C; Carello, M; Ceretto, S; Debernardi-Venon, W; Marzano, A; Rizzetto, M | 1 |
| Dixit, V; Fabrizi, F; Martin, P; Messa, P | 1 |
| Gerbes, AL; Gülberg, V; Huber, E | 1 |
| Atsukawa, M; Fukuda, T; Harimoto, H; Kanazawa, H; Katakura, T; Kidokoro, H; Kimura, Y; Matsushita, Y; Nakatsuka, K; Narahara, Y; Sakamoto, C; Taki, Y | 1 |
| Alvarez, M; Alvarez, V; Cruces, MJ; Feal, C; García-Cruz, A; Posada, C | 1 |
| Arroyo, V; Baccaro, ME; Ginès, P; Guevara, M; Marinelli, M; Martín-Llahi, M; Nazar, A; Pepin, MN; Pereira, GH; Solá, E; Terra, C | 1 |
| Duan, ZJ; Liu, LN; Wang, YD; Yang, N; Zhang, ZF; Zhao, G | 1 |
| Burroughs, AK; Cholongitas, E; Leandro, G; Marelli, L; Patch, D; Samonakis, D; Senzolo, M; Thalheimer, U; Triantos, CK | 1 |
| Asfar, P; Calès, P; Oberti, F; Radermacher, P | 1 |
| Kasturi, KS; Mittal, S; Sagi, SV; Sood, GK | 1 |
| Angus, PW; Testro, AG | 1 |
| Demirjian, S; Dobre, M; Navaneethan, SD; Sehgal, AR | 1 |
| Ackermann, O; Bernard, O; Durand, P; Habes, D; Jacquemin, E; Yousef, N | 1 |
| Abou Abbass, A; Fleming, JN | 1 |
| Bernardi, M; Bevilacqua, V; Caraceni, P; Mirici, F; Montanari, G; Pinna, AD; Santi, L | 1 |
| Kim, JW | 1 |
| Ahmed, MH; Khalil, AA; Magan, AA | 1 |
| Bexon, AS; Blei, A; Boyer, TD; Carl, D; Garcia-Tsao, G; Sanyal, AJ; Teuber, P | 1 |
| Chawla, Y; Rajekar, H | 1 |
| Bastagli, L; Bernardi, M; Borghi, C; Buccione, D; Degli Esposti, D; Di Micoli, A; Santi, V; Trevisani, F | 1 |
| Angeli, P; Boccagni, P; Boscato, N; Cavallin, M; Cillo, U; Fasolato, S; Gatta, A; Morando, F; Piano, S; Zanus, G | 1 |
| Cooper, TB; Dasta, JF; Mazur, JE | 1 |
| Biecker, E | 1 |
| Sarin, SK; Sharma, P | 1 |
| Hasper, D; Jörres, A | 1 |
| Appenrodt, B; Bexon, AS; Boyer, TD; Garcia-Tsao, G; Gülberg, V; Regenstein, F; Rossaro, L; Sanyal, AJ; Sigal, S; Teuber, P | 1 |
| Angeli, P; Cavallin, M; Morando, F; Piano, S | 1 |
| Fukui, H; Kanazawa, H; Kokubu, S; Maruyama, H; Masaki, N; Matsuzaki, Y; Mochida, S; Narahara, Y; Okita, K; Sakamoto, C; Sumino, Y; Uemura, M; Yokosuka, O | 1 |
| Alexander, GJ; Srivastava, B | 1 |
| Cioffi, O; D'Adamo, G; Fimiani, B; Guardia, DD; Izzi, A; Pagano, A; Puoti, C; Tagliamonte, MR | 1 |
| Aagaard, NK; Bendtsen, F; Grønbaek, H; Hansen, JB; Møller, S; Schmidt, L | 1 |
| Chan, AC; Chan, SC; Cheung, TT; Chok, KS; Fan, ST; Fung, JY; Lo, CM; Sharr, WW | 1 |
| Bhalla, A; Chawla, Y; Choudhary, NS; Ghosh, S; Kumar, P; Nain, CK; Sharma, AK; Sharma, N; Singh, B; Singh, V | 1 |
| Fagundes, C; Ginès, P | 1 |
| Wong, F | 1 |
| Angeli, P; Gines, P | 1 |
| Kalambokis, GN; Pappas, K; Tsianos, EV | 1 |
| Christensen, E; Christensen, K; Gluud, LL; Krag, A | 1 |
| Moreau, R | 1 |
| Barrière, E; Bernuau, J; Colle, I; Durand, F; Lebrec, D; Moreau, R; Pessione, F; Rassiat, E; Valla, DC | 1 |
| Arroyo, V; Bataller, R; Calahorra, B; Cárdenas, A; De Las Heras, D; Ginès, P; Guevara, M; Jiménez, W; Ortega, R; Rodés, J; Uriz, J | 1 |
| Jalan, R; Mookerjee, RP; Sen, S | 1 |
| Alessandria, C; Barletti, C; Fadda, M; Marzano, A; Rizzetto, M; Venon, WD | 1 |
| Chawla, A; Garg, R; Gupta, R; Jain, M; Sarin, SK; Solanki, P | 1 |
| Antoniades, C; Auzinger, G | 1 |
| Broelsch, CE; Frühauf, NR; Lang, H; Malagó, M; Saner, FH; Schäfers, RF | 1 |
| De Santis, A; Giorgi, A; Laviano, A; Riggio, O; Rossi-Fanelli, F; Vaccaro, F | 1 |
| Alessandria, C; Arroyo, V; Garcia-Valdecasas, JC; Ginès, P; Guevara, M; Navasa, M; Ortega, R; Ozdogan, O; Restuccia, T; Rimola, A; Rodés, J | 1 |
| Biglarnia, R; Broelsch, CE; Frühauf, NR; Kavuk, I; Lang, H; Malagó, M; Saner, F; Schäfers, RF | 1 |
| Aksoy, N; Akyuz, F; Besisik, F; Boztas, G; Cakaloglu, Y; Danalioglu, A; Demir, K; Karaca, C; Kaymakoglu, S; Mungan, Z; Okten, A; Ozdil, S | 1 |
| Ginès, P; Guevara, M; Terra, C; Torre, A | 1 |
| Lebrec, D | 1 |
| Elisaf, M; Kalambokis, G; Milionis, H; Tsianos, EV | 1 |
| Angeli, P; Antona, C; Brollo, L; Cillo, U; Craighero, R; Fasolato, S; Franchin, M; Gatta, A; Guarda, S; Merkel, C; Miola, E; Piccolo, F | 1 |
| Lebrec, D; Moreau, R | 1 |
| Calès, P; Dib, N; Oberti, F | 1 |
| Choi, JH; Han, WS; Hyun, JH; Jung, SW; Kim, CD; Kim, MJ; Lee, HS; Lee, JS; Lee, SW; Ryu, HS | 1 |
| Dixit, V; Fabrizi, F; Martin, P | 1 |
| Gerbes, AL; Gülberg, V | 1 |
| Christensen, E; Gluud, LL; Kjaer, MS | 1 |
| Arroyo, V; Gerbes, A; Ginès, P; Salerno, F; Wong, F | 1 |
| Alessandria, C; Balzola, F; Cerenzia, MT; Debernardi-Venon, W; Martini, S; Marzano, A; Morgando, A; Ottobrelli, A; Rizzetto, M; Todros, L | 1 |
| Angus, PW; Gow, PJ; Testro, AG; Wongseelashote, S | 1 |
| Cazzaniga, M; Gobbo, G; Salerno, F | 1 |
| Bertino, G; Castellino, P; Cosimo, BM; Ignaccolo, L; Malaguarnera, M; Neri, S; Pulvirenti, D; Siringo, S | 1 |
| Bendtsen, F; Henriksen, JH; Holstein-Rathlou, NH; Krag, A; Larsen, FS; Møller, S | 1 |
| Bernardi, M; Bracci, E; Cappa, FM; Casadio, R; Di Micoli, A; Fontana, K; Trevisani, F; Zambruni, A | 1 |
| Fabrizi, F; Martin, P; Messa, P | 1 |
| Kulicki, P; Matuszkiewicz-Rowińska, J; Niemczyk, L; Niemczyk, M; Niemczyk, S; Pyrza, M; Romejko-Ciepielewska, K | 1 |
| Arroyo, V; Díaz, F; Fábrega, E; Ginès, P; Guevara, M; Martín-Llahí, M; Monescillo, A; Pépin, MN; Rodés, J; Soriano, G; Terra, C; Torre, A | 1 |
| Appenrodt, B; Blei, A; Boyer, T; Garcia-Tsao, G; Gülberg, V; Regenstein, F; Rossaro, L; Sanyal, AJ; Sigal, S; Teuber, P | 1 |
| Groszmann, RJ; Lim, JK | 1 |
| Benhamou, JP; Durand, F; Erlinger, S; Ganne-Carrié, N; Hadengue, A; Mathurin, P | 1 |
| Auroux, J; Barbier, JP; Cellier, C; Cervoni, JP; Gadano, A; Landi, B; Lecomte, T; Simon, C | 1 |
| Durand, F; Erlinger, S; Gadano, A; Giostra, E; Hadengue, A; Lebrec, D; Moreau, R; Valla, D | 1 |
| Burroughs, A; Dagher, L; Marley, R; Moore, K; Patch, D | 1 |
| Arroyo, V; Bataller, R; Cárdenas, A; Ginès, P; Jiménez, W; Mas, A; Navasa, M; Rodés, J; Salmerón, JM; Sort, P; Uriz, J | 1 |
| Arroyo, V; Cárdenas, A; Ginès, P; Uriz, J | 1 |
| Berkelmans, I; Bourienne, A; Duhamel, C; Mauillon, J; Tranvouez, JL | 1 |
| Abergel, A; Bernard, B; Blanc, P; Bronowicki, JP; Butel, J; Cadranel, JF; Cervoni, JP; Coumaros, D; Ducloux, S; Duhamel, C; Durand, F; Fleurot, C; Giostra, E; Gurnot, D; Hadengue, A; Halimi, C; Ichaï, P; Lebrec, D; Levy, S; Moreau, R; Nouel, O; Pariente, A; Pauwels, M; Perarnau, JM; Platek, A; Poynard, T; Renard, P; Rivoal, M; Roche, J; Samuel, D; Scribe-Outtas, M; Valla, D | 1 |
| Bernard, B; Bonnard, P; Cadranel, JF; Demontis, R; di Martino, V; Fievet, P; Halimi, C; Henry-Biabaud, E; Mathurin, P; Mofredj, A; Opolon, P; Poynard, T | 1 |
| Arroyo, V | 1 |
| Calahorra, B; Ginès, P; Ortega, R | 1 |
74 review(s) available for terlipressin and Hepatorenal Syndrome
| Article | Year |
|---|---|
Hepatorenal Syndrome Type 1: From Diagnosis Ascertainment to Goal-Oriented Pharmacologic Therapy.
Topics: Acute Kidney Injury; Goals; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Terlipressin | 2022 |
Hepatorenal Syndrome: Definitions, Diagnosis, and Management.
Topics: Albumins; Female; Hepatorenal Syndrome; Humans; Kidney Transplantation; Liver Transplantation; Male; Terlipressin | 2022 |
The Comparative Effectiveness of Vasoactive Treatments for Hepatorenal Syndrome: A Systematic Review and Network Meta-Analysis.
Topics: Hepatorenal Syndrome; Humans; Midodrine; Network Meta-Analysis; Norepinephrine; Octreotide; Terlipressin; Treatment Outcome; Vasoconstrictor Agents | 2022 |
Respiratory events with terlipressin and albumin in hepatorenal syndrome: A review and clinical guidance.
Topics: Acute Kidney Injury; Albumins; Hepatorenal Syndrome; Humans; Lypressin; Terlipressin; Treatment Outcome; Vasoconstrictor Agents | 2022 |
Diagnosis and Management of Cirrhosis and Its Complications: A Review.
Topics: Adult; Ascites; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hepatic Encephalopathy; Hepatorenal Syndrome; Humans; Lactulose; Liver Cirrhosis; Liver Neoplasms; Male; Muscle Cramp; Propranolol; Randomized Controlled Trials as Topic; Sodium Potassium Chloride Symporter Inhibitors; Terlipressin; United States | 2023 |
Hepatorenal Syndrome: Pathophysiology, Diagnosis, and Treatment.
Topics: Acute Kidney Injury; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Liver Transplantation; Terlipressin; Vasoconstrictor Agents | 2023 |
Current Pharmacologic Therapies for Hepatorenal Syndrome-Acute Kidney Injury.
Topics: Acute Kidney Injury; Albumins; Hepatorenal Syndrome; Humans; Multicenter Studies as Topic; Prospective Studies; Terlipressin; United States; Vasoconstrictor Agents | 2023 |
Limited Progress in Hepatorenal Syndrome (HRS) Reversal and Survival 2002-2018: A Systematic Review and Meta-Analysis.
Topics: Adult; Albumins; Anti-Bacterial Agents; Dopamine; Drug Therapy, Combination; Female; Hepatorenal Syndrome; Humans; Male; Middle Aged; Midodrine; Norepinephrine; Octreotide; Plasma Substitutes; Randomized Controlled Trials as Topic; Regression Analysis; Survival Rate; Terlipressin; Treatment Outcome; Vasoconstrictor Agents; Young Adult | 2020 |
Peptide-based therapy in portal hypertension.
Topics: Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hepatorenal Syndrome; Humans; Hypertension, Portal; Liver Cirrhosis; Lypressin; Octreotide; Peptide Fragments; Somatostatin; Terlipressin | 2020 |
[Research progress of terlipressin in the treatment of cirrhotic ascites-related complications].
Topics: Antihypertensive Agents; Ascites; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Terlipressin; Treatment Outcome; Vasoconstrictor Agents | 2019 |
Role of Terlipressin and Albumin for Hepatorenal Syndrome in Liver Transplantation.
Topics: Albumins; Hepatorenal Syndrome; Humans; Liver Transplantation; Lypressin; Terlipressin; Vasoconstrictor Agents | 2020 |
Terlipressin has stood the test of time: Clinical overview in 2020 and future perspectives.
Topics: Hepatorenal Syndrome; Humans; Liver Cirrhosis; Lypressin; Terlipressin; Vasoconstrictor Agents | 2020 |
Renal dysfunctions and liver disease: a brief update on management with particular attention to hepatorenal syndrome.
Topics: Hepatorenal Syndrome; Humans; Liver Cirrhosis; Liver Transplantation; Terlipressin; Vasoconstrictor Agents | 2023 |
The Current Management of Hepatorenal Syndrome-Acute Kidney Injury in the United States and the Potential of Terlipressin.
Topics: Acute Kidney Injury; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Liver Transplantation; Terlipressin; United States; Vasoconstrictor Agents | 2021 |
Advances in management of hepatorenal syndrome.
Topics: Acute Kidney Injury; End Stage Liver Disease; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Terlipressin | 2021 |
Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies.
Topics: Adult; Albumins; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Hepatorenal Syndrome; Humans; Lypressin; Male; Middle Aged; Randomized Controlled Trials as Topic; Terlipressin; Treatment Outcome; Vasoconstrictor Agents | 2017 |
Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis.
Topics: Dopamine; Drug Therapy, Combination; Gastrointestinal Agents; Hepatorenal Syndrome; Humans; Lypressin; Midodrine; Network Meta-Analysis; Norepinephrine; Octreotide; Terlipressin; Treatment Outcome; Vasoconstrictor Agents | 2017 |
Comparative efficacy of vasoconstrictor therapies for type 1 hepatorenal syndrome: a network meta-analysis.
Topics: Albumins; Comparative Effectiveness Research; Female; Hepatorenal Syndrome; Humans; Lypressin; Male; Middle Aged; Norepinephrine; Odds Ratio; Plasma Substitutes; Randomized Controlled Trials as Topic; Risk Factors; Terlipressin; Treatment Outcome; Vasoconstriction; Vasoconstrictor Agents | 2017 |
Dual Organ Duel: The Hepatorenal Axis.
Topics: Acute Kidney Injury; Animals; Antihypertensive Agents; Antiviral Agents; Cytochrome P-450 Enzyme System; Hepatitis C; Hepatorenal Syndrome; Humans; Liver Diseases; Lypressin; Renal Insufficiency, Chronic; Terlipressin | 2017 |
Management of ascites and hepatorenal syndrome.
Topics: Acute Kidney Injury; Albumins; Ascites; Bacterial Translocation; Diet, Sodium-Restricted; Diuretics; Hemodynamics; Hepatorenal Syndrome; Humans; Hypertension, Portal; Hyponatremia; Liver Cirrhosis; Liver Transplantation; Lypressin; Paracentesis; Peritonitis; Portasystemic Shunt, Transjugular Intrahepatic; Splanchnic Circulation; Terlipressin; Vasoconstrictor Agents; Vasodilation | 2018 |
Terlipressin versus other vasoactive drugs for hepatorenal syndrome.
Topics: Antihypertensive Agents; Dopamine; Hepatorenal Syndrome; Humans; Lypressin; Midodrine; Norepinephrine; Octreotide; Randomized Controlled Trials as Topic; Terlipressin; Vasoconstrictor Agents | 2017 |
Pharmacological Therapies for Hepatorenal Syndrome: A Systematic Review and Meta-Analysis.
Topics: Albumins; Drug Therapy, Combination; Hepatorenal Syndrome; Humans; Infusions, Intravenous; Midodrine; Octreotide; Randomized Controlled Trials as Topic; Terlipressin; Vasoconstrictor Agents | 2018 |
Renal dysfunction and cirrhosis.
Topics: Biomarkers; Creatinine; Early Diagnosis; Hepatorenal Syndrome; Humans; Interleukin-18; Kidney Transplantation; Lipocalin-2; Liver Transplantation; Lypressin; Renal Replacement Therapy; Terlipressin; Vasoconstrictor Agents | 2017 |
Hepatorenal syndrome: the clinical impact of vasoactive therapy.
Topics: Biomarkers; Creatinine; Hepatorenal Syndrome; Humans; Lypressin; Midodrine; Norepinephrine; Octreotide; Practice Guidelines as Topic; Predictive Value of Tests; Risk Factors; Terlipressin; Treatment Outcome; Vasoconstriction; Vasoconstrictor Agents | 2018 |
Terlipressin in the treatment of hepatorenal syndrome: A systematic review and meta-analysis.
Topics: Hepatorenal Syndrome; Humans; Kidney; Lypressin; Recurrence; Terlipressin; Treatment Outcome; Vasoconstrictor Agents | 2018 |
Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome.
Topics: Abdominal Pain; Albumins; Diarrhea; Hepatorenal Syndrome; Humans; Lypressin; Randomized Controlled Trials as Topic; Terlipressin; Vasoconstrictor Agents | 2017 |
Hepatorenal syndrome.
Topics: Acute Kidney Injury; Bacterial Infections; Biomarkers; Creatinine; Fatty Acid-Binding Proteins; Hepatitis A Virus Cellular Receptor 1; Hepatorenal Syndrome; Humans; Inflammation; Interleukin-18; Lipocalin-2; Liver Cirrhosis; Risk Factors; Serum Albumin; Terlipressin; Vasoconstrictor Agents | 2018 |
Terlipressin for the treatment of hepatorenal syndrome: an overview of current evidence.
Topics: Hepatorenal Syndrome; Humans; Terlipressin; Vasoconstrictor Agents | 2019 |
Management of ascites in patients with liver cirrhosis: recent evidence and controversies.
Topics: Ascites; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Lypressin; Midodrine; Portasystemic Shunt, Transjugular Intrahepatic; Propranolol; Terlipressin | 2013 |
Results of pretransplant treatment of hepatorenal syndrome with terlipressin.
Topics: Hepatorenal Syndrome; Humans; Liver Transplantation; Lypressin; Preoperative Care; Terlipressin; Vasoconstrictor Agents | 2013 |
[Hepatorenal syndrome: diagnosis, treatment and prevention].
Topics: Albumins; Ascites; Drug Therapy, Combination; Evidence-Based Medicine; Hepatorenal Syndrome; Humans; Kidney; Liver Cirrhosis; Liver Transplantation; Lypressin; Portasystemic Shunt, Transjugular Intrahepatic; Terlipressin; Vasoconstrictor Agents | 2013 |
Ischemic skin necrosis following terlipressin therapy: report of two cases and review of the literature.
Topics: Aged; Hepatorenal Syndrome; Humans; Ischemia; Liver Cirrhosis; Lypressin; Male; Necrosis; Skin Diseases; Terlipressin; Vasoconstrictor Agents | 2012 |
[The modern possibilities of the hepato-renal syndrome treatment].
Topics: Comparative Effectiveness Research; Hemodynamics; Hepatorenal Syndrome; Humans; Hypertension, Portal; Liver Cirrhosis; Lypressin; Nitric Oxide; Outcome Assessment, Health Care; Portasystemic Shunt, Transjugular Intrahepatic; Randomized Controlled Trials as Topic; Renal Replacement Therapy; Terlipressin; Vasoconstrictor Agents | 2013 |
Acute kidney injury and hepatorenal syndrome in cirrhosis.
Topics: Acute Kidney Injury; Albumins; Ascites; Disease Progression; Drug Therapy, Combination; Early Diagnosis; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Liver Transplantation; Lypressin; Portasystemic Shunt, Transjugular Intrahepatic; Terlipressin | 2015 |
Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis.
Topics: Hepatorenal Syndrome; Humans; Lypressin; Middle Aged; Norepinephrine; Randomized Controlled Trials as Topic; Terlipressin; Treatment Outcome; Vasoconstrictor Agents | 2014 |
The Treatment of Hepatorenal Syndrome.
Topics: Adrenergic alpha-Antagonists; Albumins; Antihypertensive Agents; Drug Therapy, Combination; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Lypressin; Terlipressin | 2015 |
Noradrenaline or terlipressin for hepatorenal syndrome?
Topics: Drug Costs; Hepatorenal Syndrome; Humans; Lypressin; Norepinephrine; Randomized Controlled Trials as Topic; Terlipressin; Vasoconstrictor Agents | 2015 |
Terlipressin versus noradrenaline in the treatment of hepatorenal syndrome: systematic review with meta-analysis and full economic evaluation.
Topics: Brazil; Chi-Square Distribution; Cost Savings; Cost-Benefit Analysis; Drug Costs; Hepatorenal Syndrome; Humans; Lypressin; Models, Economic; Norepinephrine; Odds Ratio; Randomized Controlled Trials as Topic; Terlipressin; Treatment Outcome; Vasoconstrictor Agents | 2016 |
[Hepatorenal syndrome in decompensated cirrhosis : A special form of acute renal failure].
Topics: Critical Care; Fluid Therapy; Hepatorenal Syndrome; Humans; Kidney Function Tests; Liver Cirrhosis; Liver Failure; Liver Transplantation; Lypressin; Prognosis; Serum Albumin; Terlipressin; Vasoconstrictor Agents | 2016 |
Emerging hepatic syndromes: pathophysiology, diagnosis and treatment.
Topics: Acute Kidney Injury; Adrenal Insufficiency; Ascites; Creatinine; Evidence-Based Medicine; Hepatorenal Syndrome; Humans; Hypertension, Portal; Liver Cirrhosis; Liver Transplantation; Lypressin; Midodrine; Norepinephrine; Octreotide; Plasma Substitutes; Portasystemic Shunt, Transjugular Intrahepatic; Serum Albumin; Terlipressin; Vasodilator Agents; Vasopressins | 2016 |
Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1.
Topics: Albumins; Creatinine; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Lypressin; Prognosis; Randomized Controlled Trials as Topic; Terlipressin; Treatment Outcome; Vasoconstrictor Agents | 2017 |
Vasopressin analogues in the treatment of hepatorenal syndrome and gastrointestinal haemorrhage.
Topics: Animals; Blood Circulation; Gastrointestinal Hemorrhage; Hepatorenal Syndrome; Humans; Hypovolemia; Liver Cirrhosis; Lypressin; Splanchnic Circulation; Terlipressin; Vasoconstrictor Agents; Vasopressins | 2008 |
Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome.
Topics: Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hemodynamics; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Liver Failure, Acute; Lypressin; Midodrine; Norepinephrine; Octreotide; Paracentesis; Randomized Controlled Trials as Topic; Somatostatin; Terlipressin; Vasoconstrictor Agents | 2008 |
Pharmacology, clinical efficacy and safety of terlipressin in esophageal varices bleeding, septic shock and hepatorenal syndrome.
Topics: Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hepatorenal Syndrome; Humans; Lypressin; Shock, Septic; Terlipressin; Vasoconstrictor Agents | 2007 |
Terlipressin for hepatorenal syndrome: A meta-analysis of randomized trials.
Topics: Albumins; Evidence-Based Medicine; Female; Hepatorenal Syndrome; Humans; Lypressin; Male; Middle Aged; Odds Ratio; Plasma Substitutes; Randomized Controlled Trials as Topic; Survival Analysis; Terlipressin; Time Factors; Treatment Outcome; Vasoconstrictor Agents | 2009 |
[Meta-analysis of terlipressin in treatment of hepatorenal syndrome: an update].
Topics: Hepatorenal Syndrome; Humans; Lypressin; Norepinephrine; Prognosis; Randomized Controlled Trials as Topic; Terlipressin; Treatment Outcome | 2009 |
The effects of vasopressin and its analogues on the liver and its disorders in the critically ill.
Topics: Critical Care; Critical Illness; Hemodynamics; Hepatorenal Syndrome; Humans; Intensive Care Units; Liver; Liver Cirrhosis; Lypressin; Risk Factors; Shock, Septic; Terlipressin; Varicose Veins; Vasoconstrictor Agents; Vasopressins | 2010 |
Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials.
Topics: Biomarkers; Creatinine; Female; Hepatorenal Syndrome; Humans; Lypressin; Male; Middle Aged; Randomized Controlled Trials as Topic; Recurrence; Risk Assessment; Risk Factors; Terlipressin; Time Factors; Treatment Outcome; Vasoconstrictor Agents | 2010 |
Terlipressin in hepatorenal syndrome: a systematic review and meta-analysis.
Topics: Antihypertensive Agents; Diagnosis, Differential; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Lypressin; Terlipressin; Treatment Outcome | 2011 |
Hepatorenal syndrome: a comprehensive overview for the critical care nurse.
Topics: Critical Care; Disease Progression; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Liver Transplantation; Lypressin; Portasystemic Shunt, Transjugular Intrahepatic; Risk Factors; Terlipressin; Vasoconstrictor Agents; Vasodilation | 2010 |
Terlipressin and hepatorenal syndrome: what is important for nephrologists and hepatologists.
Topics: Antihypertensive Agents; Baroreflex; Cardiac Output; Hemodynamics; Hepatorenal Syndrome; Humans; Lypressin; Meta-Analysis as Topic; Renin-Angiotensin System; Sympathetic Nervous System; Terlipressin; Vasoconstrictor Agents | 2010 |
Terlipressin in hepatorenal syndrome: Evidence for present indications.
Topics: Evidence-Based Medicine; Hemodynamics; Hepatorenal Syndrome; Humans; Kidney; Liver Transplantation; Lypressin; Risk Assessment; Terlipressin; Time Factors; Treatment Outcome; Vasoconstrictor Agents | 2011 |
Terlipressin in hepatorenal syndrome.
Topics: Arginine Vasopressin; Hepatorenal Syndrome; Humans; Lypressin; Terlipressin; Treatment Outcome; Vasoconstrictor Agents | 2011 |
New insights into the management of hepato-renal syndrome.
Topics: Disease Management; Hepatorenal Syndrome; Humans; Lypressin; Midodrine; Norepinephrine; Renal Dialysis; Terlipressin | 2011 |
Hepatorenal syndrome.
Topics: Albumins; Hepatorenal Syndrome; Humans; Liver Transplantation; Lypressin; Terlipressin; Vasoconstrictor Agents | 2011 |
Renal failure in chronic liver disease and the hepatorenal syndrome.
Topics: Bilirubin; Chronic Disease; Evidence-Based Practice; Fluid Therapy; Hemodynamics; Hepatorenal Syndrome; Humans; Kidney; Liver; Liver Cirrhosis; Liver Transplantation; Lypressin; Monitoring, Physiologic; Patient Selection; Portasystemic Shunt, Surgical; Regional Blood Flow; Renal Insufficiency; Serum Albumin; Severity of Illness Index; Terlipressin; Vasoconstrictor Agents | 2011 |
Recent advances in our understanding of hepatorenal syndrome.
Topics: Comorbidity; Hemodynamics; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Liver Transplantation; Lypressin; Norepinephrine; Terlipressin; Treatment Outcome; Vasoconstrictor Agents | 2012 |
Hepatorenal syndrome, MELD score and liver transplantation: an evolving issue with relevant implications for clinical practice.
Topics: Albumins; Antihypertensive Agents; Hepatorenal Syndrome; Humans; Liver Transplantation; Lypressin; Severity of Illness Index; Terlipressin; Waiting Lists | 2012 |
Terlipressin for hepatorenal syndrome.
Topics: Albumins; Hepatorenal Syndrome; Humans; Lypressin; Randomized Controlled Trials as Topic; Terlipressin; Vasoconstrictor Agents | 2012 |
Hepatorenal syndrome in patients with cirrhosis.
Topics: Hepatorenal Syndrome; Humans; Liver Cirrhosis; Liver Transplantation; Lypressin; Primary Prevention; Prognosis; Terlipressin; Treatment Outcome; Vasoconstrictor Agents | 2002 |
Review article: pharmacological treatment of hepatorenal syndrome.
Topics: Adrenergic alpha-Agonists; Hepatorenal Syndrome; Humans; Lypressin; Terlipressin; Vasoconstrictor Agents | 2004 |
Review article: future indications for terlipressin therapy.
Topics: Animals; Cardiopulmonary Resuscitation; Hepatorenal Syndrome; Humans; Lypressin; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Paracentesis; Rats; Shock, Septic; Terlipressin; Vasoconstrictor Agents | 2004 |
The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond.
Topics: Adrenergic alpha-Agonists; Cardiovascular Diseases; Drug Therapy, Combination; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Lypressin; Paracentesis; Shock, Septic; Splanchnic Circulation; Terlipressin; Vasoconstrictor Agents; Vasodilation | 2006 |
Current management of the complications of portal hypertension: variceal bleeding and ascites.
Topics: Algorithms; Anti-Bacterial Agents; Ascites; Collateral Circulation; Diuretics; Endoscopy, Gastrointestinal; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hepatorenal Syndrome; Hormones; Hypertension, Portal; Liver Cirrhosis; Lypressin; Peritonitis; Portasystemic Shunt, Transjugular Intrahepatic; Sclerotherapy; Secondary Prevention; Somatostatin; Spironolactone; Terlipressin; Vascular Resistance; Vasoconstrictor Agents; Vasodilation; Vasopressins | 2006 |
Meta-analysis: terlipressin therapy for the hepatorenal syndrome.
Topics: Clinical Trials as Topic; Hepatorenal Syndrome; Humans; Lypressin; Recurrence; Research Design; Terlipressin; Treatment Outcome; Vasoconstrictor Agents | 2006 |
[Renal impairment in liver diseases].
Topics: Diagnosis, Differential; Hepatorenal Syndrome; Humans; Kidney Transplantation; Liver Cirrhosis; Lypressin; Portasystemic Shunt, Transjugular Intrahepatic; Prognosis; Renal Insufficiency; Serum Albumin; Terlipressin | 2006 |
Terlipressin for hepatorenal syndrome.
Topics: Hepatorenal Syndrome; Humans; Lypressin; Randomized Controlled Trials as Topic; Terlipressin; Vasoconstrictor Agents | 2006 |
Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis.
Topics: Albumins; Hepatorenal Syndrome; Humans; Infusions, Parenteral; Liver Cirrhosis; Liver Transplantation; Lypressin; Portasystemic Shunt, Transjugular Intrahepatic; Renal Dialysis; Terlipressin; Vasoconstrictor Agents | 2007 |
Recent advances in the management of hepato-renal syndrome (HRS).
Topics: Glomerular Filtration Rate; Hepatorenal Syndrome; Humans; Liver Transplantation; Lypressin; Meta-Analysis as Topic; Portasystemic Shunt, Transjugular Intrahepatic; Renal Dialysis; Terlipressin; Time Factors; Vasoconstrictor Agents | 2007 |
Terlipressin may influence the outcome of hepatorenal syndrome complicating alcoholic hepatitis.
Topics: Aged; Chronic Disease; Female; Hepatitis, Alcoholic; Hepatorenal Syndrome; Humans; Lypressin; Remission Induction; Terlipressin | 1997 |
Review article: pharmacological treatment of the hepatorenal syndrome in cirrhotic patients.
Topics: Disease Progression; Felypressin; Hepatitis, Alcoholic; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Liver Transplantation; Lypressin; Octreotide; Renal Agents; Terlipressin; Vasoconstrictor Agents | 2000 |
Hepatorenal syndrome.
Topics: Fibrosis; Hepatorenal Syndrome; Homeostasis; Humans; Liver Transplantation; Lypressin; Predictive Value of Tests; Terlipressin; Vasoconstrictor Agents | 2000 |
[Physiopathology of refractory ascites and the hepatorenal syndrome].
Topics: Ascites; Glomerular Filtration Rate; Hepatorenal Syndrome; Humans; Hypertension, Portal; Hypotension; Kidney; Liver Cirrhosis; Lypressin; Ornipressin; Paracentesis; Peritoneovenous Shunt; Peritonitis; Plasma Substitutes; Renin-Angiotensin System; Splanchnic Circulation; Sympathetic Nervous System; Tachycardia; Terlipressin; Vasoconstriction | 2002 |
[Vasoconstrictors in the treatment of hepatorenal syndrome].
Topics: Adrenergic alpha-Agonists; Albumins; Drug Evaluation; Drug Therapy, Combination; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Lypressin; Midodrine; Octreotide; Ornipressin; Pilot Projects; Renal Circulation; Terlipressin; Vasoconstrictor Agents | 2002 |
37 trial(s) available for terlipressin and Hepatorenal Syndrome
| Article | Year |
|---|---|
Terlipressin and the Treatment of Hepatorenal Syndrome: How the CONFIRM Trial Moves the Story Forward.
Topics: Acute Kidney Injury; Female; Hepatorenal Syndrome; Humans; Lypressin; Male; Terlipressin; Treatment Outcome; Vasoconstrictor Agents | 2022 |
Terlipressin use and respiratory failure in patients with hepatorenal syndrome type 1 and severe acute-on-chronic liver failure.
Topics: Acute-On-Chronic Liver Failure; Albumins; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Lypressin; Respiratory Insufficiency; Terlipressin; Vasoconstrictor Agents | 2022 |
Liver-HERO: hepatorenal syndrome-acute kidney injury (HRS-AKI) treatment with transjugular intrahepatic portosystemic shunt in patients with cirrhosis-a randomized controlled trial.
Topics: Acute Kidney Injury; Albumins; Ascites; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Portasystemic Shunt, Transjugular Intrahepatic; Prospective Studies; Quality of Life; Terlipressin | 2023 |
Combination of terlipressin and noradrenaline versus terlipressin in hepatorenal syndrome with early non-response to terlipressin infusion: A randomized trial.
Topics: Hepatorenal Syndrome; Humans; Norepinephrine; Terlipressin; Treatment Outcome; Vasoconstrictor Agents | 2023 |
Effectiveness of terlipressin for prevention of complications after major liver resection - A randomized placebo-controlled trial.
Topics: Ascites; Female; Hepatorenal Syndrome; Humans; Male; Middle Aged; Terlipressin; Vasoconstrictor Agents | 2020 |
Role of Terlipressin and Albumin for Hepatorenal Syndrome in Liver Transplantation.
Topics: Albumins; Hepatorenal Syndrome; Humans; Liver Transplantation; Lypressin; Terlipressin; Vasoconstrictor Agents | 2020 |
Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome.
Topics: Albumins; Combined Modality Therapy; Double-Blind Method; Female; Hepatorenal Syndrome; Humans; Infusions, Intravenous; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Renal Replacement Therapy; Respiratory Insufficiency; Terlipressin; Treatment Outcome; Vasoconstrictor Agents | 2021 |
Noradrenaline versus terlipressin in the management of type 1 hepatorenal syndrome: A randomized controlled study.
Topics: Adult; Aged; Albumins; Creatinine; Female; Hepatorenal Syndrome; Humans; Male; Middle Aged; Norepinephrine; Terlipressin; Treatment Outcome; Vasoconstrictor Agents | 2018 |
Reduction in acute kidney injury stage predicts survival in patients with type-1 hepatorenal syndrome.
Topics: Acute Kidney Injury; Aged; Double-Blind Method; Female; Hepatorenal Syndrome; Humans; Male; Middle Aged; Prognosis; Survival Rate; Terlipressin; Vasoconstrictor Agents | 2020 |
Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study.
Topics: Adult; Biomarkers; Chi-Square Distribution; Creatinine; Female; Hemodynamics; Hepatorenal Syndrome; Humans; India; Kaplan-Meier Estimate; Logistic Models; Lypressin; Male; Middle Aged; Multivariate Analysis; Norepinephrine; Pilot Projects; Sodium; Terlipressin; Tertiary Care Centers; Time Factors; Treatment Outcome; Urination; Vasoconstrictor Agents | 2013 |
[A comparative study of high-or low-dose terlipressin therapy in patients with cirrhosis and type 1 hepatorenal syndrome].
Topics: Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Female; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Lypressin; Male; Middle Aged; Retrospective Studies; Terlipressin; Treatment Outcome; Young Adult | 2014 |
[Response to Terlipressin and albumin is associated with improved outcome in patients with cirrhosis and hepatorenal syndrome].
Topics: Adult; Aged; Albumins; Antihypertensive Agents; Drug Therapy, Combination; Female; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Lypressin; Male; Middle Aged; Terlipressin; Treatment Outcome | 2015 |
Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.
Topics: Aged; Albumins; Analysis of Variance; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatorenal Syndrome; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Kidney Function Tests; Liver Function Tests; Lypressin; Male; Middle Aged; Midodrine; Octreotide; Predictive Value of Tests; Survival Analysis; Terlipressin; Treatment Outcome | 2015 |
Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study.
Topics: Aged; Female; Hepatorenal Syndrome; Humans; Infusions, Intravenous; Italy; Lypressin; Male; Middle Aged; Terlipressin; Vasoconstrictor Agents | 2016 |
Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.
Topics: Adult; Albumins; Canada; Drug Therapy, Combination; Female; Hepatorenal Syndrome; Humans; Kidney; Kidney Function Tests; Liver Cirrhosis; Lypressin; Male; Middle Aged; Terlipressin; Treatment Outcome; Vasoconstrictor Agents | 2016 |
Effect of different therapeutic modalities on systemic, renal, and hepatic hemodynamics and short-term outcomes in cirrhotic patients with spontaneous bacterial peritonitis.
Topics: Adult; Bacterial Infections; Drug Therapy, Combination; Female; Hemodynamics; Hepatorenal Syndrome; Humans; Liver Circulation; Liver Cirrhosis; Lypressin; Male; Middle Aged; Midodrine; Peritonitis; Renal Circulation; Serum Albumin; Terlipressin; Treatment Outcome; Vasoconstrictor Agents | 2016 |
Terlipressin Improves Renal Function and Reverses Hepatorenal Syndrome in Patients With Systemic Inflammatory Response Syndrome.
Topics: Aged; Canada; Female; Hepatorenal Syndrome; Humans; Lypressin; Male; Middle Aged; Placebos; Retrospective Studies; Survival Analysis; Systemic Inflammatory Response Syndrome; Terlipressin; Treatment Outcome; United States; Vasoconstrictor Agents | 2017 |
Noradrenaline is as Effective as Terlipressin in Hepatorenal Syndrome Type 1: A Prospective, Randomized Trial.
Topics: Adrenergic alpha-Agonists; Creatinine; Female; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Lypressin; Male; Middle Aged; Norepinephrine; Prospective Studies; Terlipressin; Vasoconstrictor Agents | 2016 |
An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response.
Topics: Antihypertensive Agents; Blood Pressure; Creatinine; Female; Hepatorenal Syndrome; Humans; Lypressin; Male; Middle Aged; Norepinephrine; Pilot Projects; Renin; Terlipressin; Treatment Outcome; Vasoconstrictor Agents | 2008 |
Effects of terlipressin on the aquaretic system: evidence of antidiuretic effects.
Topics: Adolescent; Adult; Aged; Antidiuretic Agents; Aquaporin 2; Arginine Vasopressin; Blood Pressure; Creatinine; Cyclic AMP; Drinking; Female; Hepatorenal Syndrome; Humans; Kidney; Lithium; Lypressin; Male; Middle Aged; Osmolar Concentration; Receptors, Vasopressin; Sodium; Terlipressin; Urine; Vasoconstrictor Agents; Water; Water-Electrolyte Balance; Young Adult | 2008 |
Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis.
Topics: Aged; Blood Pressure; Cardiac Output; Female; Heart Rate; Hemodynamics; Hepatorenal Syndrome; Humans; Hypertension, Portal; Injections, Intravenous; Liver Circulation; Liver Cirrhosis; Lypressin; Male; Middle Aged; Neurotransmitter Agents; Placebo Effect; Renal Circulation; Terlipressin; Treatment Outcome; Ultrasonography, Doppler; Vascular Resistance; Vasoconstrictor Agents | 2009 |
Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics.
Topics: Adult; Albumins; Blood Pressure; Creatinine; Double-Blind Method; Female; Hemodynamics; Hepatorenal Syndrome; Humans; Lypressin; Male; Prospective Studies; Terlipressin; Vasoconstrictor Agents | 2011 |
Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1.
Topics: Albumins; Cohort Studies; Hepatorenal Syndrome; Humans; Liver Failure; Liver Transplantation; Lypressin; Prognosis; Survival Rate; Terlipressin; Vasoconstrictor Agents | 2011 |
The efficacy and safety of terlipressin and albumin in patients with type 1 hepatorenal syndrome: a multicenter, open-label, explorative study.
Topics: Aged; Albumins; Antihypertensive Agents; Creatinine; Drug Therapy, Combination; Female; Hepatorenal Syndrome; Humans; Japan; Liver Cirrhosis; Lypressin; Male; Middle Aged; Norepinephrine; Prospective Studies; Renin; Survival Rate; Terlipressin; Treatment Outcome | 2012 |
The use of terlipressin in cirrhotic patients with refractory ascites and normal renal function: a multicentric study.
Topics: Adult; Aged; Albumins; Ascites; Diuretics; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatorenal Syndrome; Humans; Kidney; Liver Cirrhosis; Lypressin; Male; Middle Aged; Prospective Studies; Severity of Illness Index; Terlipressin; Treatment Outcome; Vasoconstrictor Agents | 2011 |
Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study.
Topics: Adult; Aged; Blood Pressure; Female; Hepatorenal Syndrome; Humans; Lypressin; Male; Middle Aged; Norepinephrine; Terlipressin | 2012 |
Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study.
Topics: Adult; Aged; Albumins; Antihypertensive Agents; Drug Therapy, Combination; Female; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Lypressin; Male; Middle Aged; Prospective Studies; Recurrence; Survival Analysis; Terlipressin | 2002 |
Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2.
Topics: Female; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Lypressin; Male; Middle Aged; Portasystemic Shunt, Surgical; Prospective Studies; Terlipressin; Treatment Outcome; Urination; Vasoconstrictor Agents | 2002 |
Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial.
Topics: Blood Pressure; Creatinine; Female; Hepatorenal Syndrome; Humans; Kidney Function Tests; Liver Function Tests; Lypressin; Male; Middle Aged; Prospective Studies; Single-Blind Method; Survival Analysis; Terlipressin; Treatment Outcome; Vasoconstrictor Agents | 2003 |
Terlipressin and gelafundin: safe therapy of hepatorenal syndrome.
Topics: Antihypertensive Agents; Creatinine; Gelatin; Glomerular Filtration Rate; Hemodynamics; Hepatorenal Syndrome; Humans; Injections, Intravenous; Kidney; Kidney Function Tests; Lypressin; Pilot Projects; Plasma Substitutes; Terlipressin; Treatment Outcome | 2004 |
Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost.
Topics: Administration, Oral; Albumins; Anti-Bacterial Agents; Antihypertensive Agents; Ceftazidime; Ciprofloxacin; Female; Health Care Costs; Hepatorenal Syndrome; Humans; Infusions, Intravenous; Length of Stay; Liver Cirrhosis; Lypressin; Male; Middle Aged; Peritonitis; Terlipressin | 2006 |
Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study.
Topics: Antihypertensive Agents; Female; Health Care Costs; Hepatorenal Syndrome; Humans; Lypressin; Male; Middle Aged; Norepinephrine; Pilot Projects; Prospective Studies; Recurrence; Survival Analysis; Terlipressin; Treatment Outcome; Vasoconstrictor Agents | 2007 |
Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome.
Topics: Ascites; Double-Blind Method; Female; Glomerular Filtration Rate; Hepatorenal Syndrome; Humans; Kidney; Kidney Diseases; Liver Cirrhosis, Alcoholic; Lypressin; Male; Middle Aged; Receptors, Vasopressin; Recovery of Function; Terlipressin; Vasoconstrictor Agents | 2007 |
Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.
Topics: Adolescent; Adult; Aged; Albumins; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatorenal Syndrome; Humans; Injections, Intravenous; Kidney Function Tests; Liver Cirrhosis; Lypressin; Male; Middle Aged; Retrospective Studies; Shock, Septic; Survival Rate; Terlipressin; Time Factors; Treatment Outcome; United States; Vasoconstrictor Agents | 2008 |
A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome.
Topics: Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Germany; Hepatorenal Syndrome; Humans; Injections, Intravenous; Kidney Function Tests; Lypressin; Male; Middle Aged; Prospective Studies; Russia; Severity of Illness Index; Shock, Septic; Survival Rate; Terlipressin; Treatment Outcome; United States; Vasoconstrictor Agents | 2008 |
Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome.
Topics: Atrial Natriuretic Factor; Blood Pressure; Cross-Over Studies; Double-Blind Method; Female; Glomerular Filtration Rate; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Lypressin; Male; Middle Aged; Sodium; Terlipressin | 1998 |
Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome.
Topics: Adult; Aged; Blood Pressure; Creatinine; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatorenal Syndrome; Humans; Injections, Intravenous; Lypressin; Male; Middle Aged; Norepinephrine; Pilot Projects; Renin; Serum Albumin; Terlipressin; Vasoconstrictor Agents | 2000 |
106 other study(ies) available for terlipressin and Hepatorenal Syndrome
| Article | Year |
|---|---|
Standardized versus nonstandardized pharmacologic treatment for hepatorenal syndrome.
Topics: Hepatorenal Syndrome; Humans; Lypressin; Terlipressin | 2021 |
Terlipressin: Hopes Fulfilled or Dashed?
Topics: Hepatorenal Syndrome; Humans; Terlipressin | 2022 |
Board Review Vignette: Lessons Learned in the Management of Hepatorenal Syndrome Type 1 With Terlipressin.
Topics: Hepatorenal Syndrome; Humans; Lypressin; Terlipressin; Treatment Outcome; Vasoconstrictor Agents | 2022 |
Safety and efficacy of terlipressin in acute-on-chronic liver failure with hepatorenal syndrome-acute kidney injury (HRS-AKI): a prospective cohort study.
Topics: Acute Kidney Injury; Acute-On-Chronic Liver Failure; Adult; Hepatorenal Syndrome; Humans; Lypressin; Prospective Studies; Terlipressin; Vasoconstrictor Agents | 2022 |
Duodenal Necrosis and Nonvariceal Digestive Bleeding After Terlipressin Administration for Treatment of Hepatorenal Syndrome: a Case Report of a Novel Side Effect of a Commonly Used Drug.
Topics: Creatinine; End Stage Liver Disease; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hepatorenal Syndrome; Humans; Ischemia; Liver Cirrhosis; Lypressin; Male; Middle Aged; Necrosis; Severity of Illness Index; Terlipressin; Vasoconstrictor Agents | 2022 |
[Practice guidance for the use of terlipressin for liver cirrhosis-related complications (2021)].
Topics: Electrolytes; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Lypressin; Terlipressin; Vasoconstrictor Agents | 2022 |
Terlipressin for hepatorenal syndrome: opportunities and challenges.
Topics: Hepatorenal Syndrome; Humans; Lypressin; Terlipressin; Vasoconstrictor Agents | 2023 |
Early treatment with terlipressin in patients with hepatorenal syndrome yields improved clinical outcomes in North American studies.
Topics: Creatinine; Hepatorenal Syndrome; Humans; Lypressin; North America; Terlipressin; Treatment Outcome; Vasoconstrictor Agents | 2023 |
Practical Management of HRS-AKI in the Era of Terlipressin: What the Gastroenterologist Needs to Know.
Topics: Acute Kidney Injury; Gastroenterologists; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Terlipressin; Treatment Outcome; Vasoconstrictor Agents | 2023 |
First Drug for Treating Hepatorenal Syndrome.
Topics: Hepatorenal Syndrome; Humans; Lypressin; Terlipressin; Treatment Outcome; Vasoconstrictor Agents | 2023 |
Responsiveness to Vasoconstrictor Therapy in Hepatorenal Syndrome Type 1.
Topics: Hepatorenal Syndrome; Humans; Liver Cirrhosis; Terlipressin; Vasoconstrictor Agents | 2023 |
Terlipressin Treatment Is Associated With Reversal of Hepatorenal Syndrome in Patients With Alcoholic Hepatitis.
Topics: Albumins; Hepatitis, Alcoholic; Hepatorenal Syndrome; Humans; Lypressin; Terlipressin; Treatment Outcome; Vasoconstrictor Agents | 2023 |
Terlipressin (Terlivaz) for hepatorenal syndrome.
Topics: Hepatorenal Syndrome; Humans; Octreotide; Terlipressin; Treatment Outcome; Vasoconstrictor Agents | 2023 |
Higher Respiratory Complications in Alcoholic Hepatitis Patients With Hepatorenal Syndrome When Treated With Terlipressin: Is it Safe?
Topics: Hepatitis, Alcoholic; Hepatorenal Syndrome; Humans; Lypressin; Terlipressin; Treatment Outcome; Vasoconstrictor Agents | 2023 |
The Effect of Terlipressin on Renal Replacement Therapy in Patients with Hepatorenal Syndrome.
Topics: Continuous Renal Replacement Therapy; Hepatorenal Syndrome; Humans; Lypressin; Terlipressin; Vasoconstrictor Agents | 2023 |
Outcomes of patients with hepatorenal syndrome undergoing liver transplantation in the era of terlipressin.
Topics: Creatinine; Hepatorenal Syndrome; Humans; Liver Transplantation; Lypressin; Retrospective Studies; Terlipressin; Treatment Outcome; Vasoconstrictor Agents | 2023 |
Good Enough? Terlipressin, Hepatorenal Syndrome, and the Usage of RRT.
Topics: Hepatorenal Syndrome; Humans; Terlipressin | 2023 |
Treatment-Related Cost Analysis of Terlipressin for Adults with Hepatorenal Syndrome with Rapid Reduction in Kidney Function.
Topics: Adult; Albumins; Health Care Costs; Hepatorenal Syndrome; Humans; Kidney; Norepinephrine; Terlipressin; Treatment Outcome; Vasoconstrictor Agents | 2023 |
What is the role for terlipressin in hepatorenal syndrome?
Topics: Hepatorenal Syndrome; Humans; Liver Cirrhosis; Terlipressin; Treatment Outcome; Vasoconstrictor Agents | 2023 |
Efficacy of treatment with terlipressin plus albumin in hepatorenal syndrome diagnosed with the new acute kidney injury versus the conventional criteria.
Topics: Acute Kidney Injury; Albumins; Drug Therapy, Combination; Hepatorenal Syndrome; Humans; Kaplan-Meier Estimate; Practice Guidelines as Topic; Retrospective Studies; Terlipressin; Treatment Outcome; Vasoconstrictor Agents | 2019 |
Real-world treatment patterns and outcomes using terlipressin in 203 patients with the hepatorenal syndrome.
Topics: Adult; Aged; Creatinine; Female; Hepatorenal Syndrome; Humans; Liver Transplantation; Male; Middle Aged; Renal Dialysis; Terlipressin; Treatment Outcome; United Kingdom; Vasoconstrictor Agents | 2020 |
Terlipressin for Type 1 Hepatorenal Syndrome.
Topics: Hepatorenal Syndrome; Humans; Terlipressin; Vasoconstrictor Agents | 2020 |
A study on clinical outcomes of combination of terlipressin and albumin in Hepatorenal Syndrome.
Topics: Aged; Albumins; Drug Therapy, Combination; Female; Hepatorenal Syndrome; Humans; India; Kidney; Kidney Function Tests; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Quality of Life; Recurrence; Terlipressin; Tertiary Care Centers; Treatment Outcome; Vasoconstrictor Agents | 2020 |
Use of terlipressin in critically ill children with liver disease.
Topics: Acute Kidney Injury; Adolescent; Ascites; Child; Creatinine; Critical Illness; Cyanosis; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Hepatorenal Syndrome; Humans; Intensive Care Units, Pediatric; Ischemia; Liver Diseases; Male; Terlipressin; Vasoconstrictor Agents | 2020 |
Editorial: treating hepatorenal syndrome-a window and the views.
Topics: Hepatorenal Syndrome; Humans; Lypressin; Terlipressin; Vasoconstrictor Agents | 2020 |
Editorial: treating hepatorenal syndrome-a window and the views. Authors' reply.
Topics: Hepatorenal Syndrome; Humans; Terlipressin; Vasoconstrictor Agents | 2020 |
Response to Terlipressin and Albumin Is Associated With Improved Liver Transplant Outcomes in Patients With Hepatorenal Syndrome.
Topics: Acute Kidney Injury; Albumins; Female; Hepatorenal Syndrome; Humans; Liver Transplantation; Male; Middle Aged; Renal Replacement Therapy; Terlipressin; Treatment Outcome; Vasoconstrictor Agents | 2021 |
Safety and efficacy of outpatient continuous terlipressin infusion for the treatment of portal hypertensive complications in cirrhosis.
Topics: Ascites; End Stage Liver Disease; Hepatorenal Syndrome; Humans; Hydrothorax; Liver Cirrhosis; Lypressin; Outpatients; Severity of Illness Index; Terlipressin; Treatment Outcome; Vasoconstrictor Agents | 2022 |
Prevalence and short-term outcome of hepatorenal syndrome: A 9-year experience in a high-complexity hospital in Colombia.
Topics: Adult; Aged; Colombia; Female; Hepatorenal Syndrome; Humans; Male; Middle Aged; Norepinephrine; Prevalence; Retrospective Studies; Terlipressin; Treatment Outcome; Vasoconstrictor Agents | 2020 |
Letter: HRS-AKI-a frequent misdiagnosis in the real world setting? Authors' reply.
Topics: Acute Kidney Injury; Diagnostic Errors; Hepatorenal Syndrome; Humans; Terlipressin | 2020 |
Letter: HRS-AKI - a frequent misdiagnosis in the real-world setting?
Topics: Acute Kidney Injury; Diagnostic Errors; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Terlipressin | 2020 |
Ischemic skin necrosis secondary to the use of terlipressin.
Topics: Hepatorenal Syndrome; Humans; Liver Cirrhosis; Lypressin; Male; Middle Aged; Necrosis; Terlipressin; Vasoconstrictor Agents | 2021 |
An investigation of reconstituted terlipressin infusion stability for use in hepatorenal syndrome.
Topics: Drug Stability; Hepatorenal Syndrome; Humans; Infusion Pumps; Infusions, Intravenous; Terlipressin; Vasoconstrictor Agents | 2020 |
Evidence-based protocol for diagnosis and treatment of hepatorenal syndrome is independently associated with lower mortality.
Topics: Albumins; Analysis of Variance; Aspartate Aminotransferases; Clinical Protocols; Evidence-Based Medicine; Female; Hepatorenal Syndrome; Humans; Male; Middle Aged; Proportional Hazards Models; Terlipressin; Tertiary Care Centers; Vasoconstrictor Agents | 2022 |
Topics: Albumins; Hepatorenal Syndrome; Humans; Terlipressin | 2021 |
Toward Norepinephrine as a First-Line Treatment for All Hospitalized Patients With Hepatorenal Syndrome.
Topics: Hepatorenal Syndrome; Humans; Liver Transplantation; Lypressin; Norepinephrine; Terlipressin | 2021 |
Treatment of Severe Acute on Chronic Liver Failure: Management of Organ Failures, Investigational Therapeutics, and the Role of Liver Transplantation.
Topics: Acute-On-Chronic Liver Failure; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Liver Transplantation; Prognosis; Terlipressin | 2021 |
Letter to the Editor: Response to Terlipressin Plus Albumin in Hepatorenal Syndrome-Need a Closer Look!
Topics: Albumins; Hepatorenal Syndrome; Humans; Terlipressin; Vasoconstrictor Agents | 2021 |
End-stage liver disease: Management of hepatorenal syndrome.
Topics: Acute Kidney Injury; End Stage Liver Disease; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Terlipressin; Vasoconstrictor Agents | 2021 |
Letter: real-world use of terlipressin in patients with the hepatorenal syndrome-authors' reply.
Topics: Hepatorenal Syndrome; Humans; Lypressin; Terlipressin; Vasoconstrictor Agents | 2021 |
Letter: real-world use of terlipressin in patients with hepatorenal syndrome.
Topics: Hepatorenal Syndrome; Humans; Lypressin; Terlipressin; Vasoconstrictor Agents | 2021 |
Terlipressin for hepatorenal syndrome: ready for prime time.
Topics: Hepatorenal Syndrome; Humans; Lypressin; Terlipressin; Vasoconstrictor Agents | 2017 |
Editorial: tackling hepatorenal syndrome-terlipressin for all, or time for a stratified approach?
Topics: Hepatorenal Syndrome; Humans; Lypressin; Terlipressin; Vasoconstrictor Agents | 2017 |
Terlipressin is superior to midodrine/octreotide for hepatorenal syndrome type 1.
Topics: Drug Therapy, Combination; Hepatorenal Syndrome; Humans; Lypressin; Midodrine; Octreotide; Retrospective Studies; Terlipressin; Treatment Outcome; Vasoconstrictor Agents | 2017 |
Association Between Grade of Acute on Chronic Liver Failure and Response to Terlipressin and Albumin in Patients With Hepatorenal Syndrome.
Topics: Acute-On-Chronic Liver Failure; Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Europe; Female; Hepatorenal Syndrome; Humans; Male; Middle Aged; Retrospective Studies; Serum Albumin, Human; Severity of Illness Index; Terlipressin; Treatment Outcome; Young Adult | 2018 |
Systemic hemodynamic response to terlipressin predicts development of hepatorenal syndrome and survival in advanced cirrhosis.
Topics: Aged; Area Under Curve; Arterial Pressure; Ascites; Cardiac Output; Female; Hemodynamics; Hepatorenal Syndrome; Humans; Linear Models; Liver Cirrhosis; Logistic Models; Lypressin; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Proportional Hazards Models; Reproducibility of Results; Retrospective Studies; Risk Factors; ROC Curve; Terlipressin; Time Factors; Vascular Resistance; Vasoconstrictor Agents | 2018 |
Predictors of Response to Terlipressin in Hepatorenal Syndrome.
Topics: Hepatorenal Syndrome; Humans; Lypressin; Terlipressin; Vasoconstrictor Agents | 2018 |
When Should We Stop Treatment With Terlipressin and Albumin for Patients With Hepatorenal Syndrome?
Topics: Acute-On-Chronic Liver Failure; Albumins; Hepatorenal Syndrome; Humans; Lypressin; Terlipressin | 2018 |
Response to Terlipressin in Hepatorenal Syndrome: Predict to Prognosticate!
Topics: Hepatorenal Syndrome; Humans; Lypressin; Terlipressin; Vasoconstrictor Agents | 2018 |
Noradrenaline for Hepatorenal Syndrome in Patients With Acute on Chronic Liver Failure: Hope Remains!
Topics: Acute Kidney Injury; Acute-On-Chronic Liver Failure; Hepatorenal Syndrome; Humans; Norepinephrine; Terlipressin | 2018 |
[Severe reversible penile ischaemia after terlipressin treatment of hepatorenal syndrome].
Topics: Acute Kidney Injury; Aged; Hepatorenal Syndrome; Humans; Ischemia; Liver Cirrhosis, Alcoholic; Lypressin; Male; Penis; Terlipressin; Vasoconstrictor Agents | 2018 |
Characterization of inflammatory response in hepatorenal syndrome: Relationship with kidney outcome and survival.
Topics: Acute Kidney Injury; Acute-On-Chronic Liver Failure; Aged; Albumins; Biomarkers; Cytokines; Female; Hepatorenal Syndrome; Humans; Inflammation; Kidney; Liver; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prospective Studies; Severity of Illness Index; Spain; Survival Analysis; Terlipressin; Vasoconstrictor Agents | 2019 |
Terlipressin-Induced Peripheral Cyanosis in a Patient with Liver Cirrhosis and Hepatorenal Syndrome.
Topics: Aged; Cyanosis; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Male; Terlipressin; Vasoconstrictor Agents | 2019 |
Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2.
Topics: Aged; Albumins; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatorenal Syndrome; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Recurrence; Remission Induction; Terlipressin; Treatment Outcome; Vasoconstrictor Agents | 2019 |
Ischemic Skin Necrosis in Hepatorenal Syndrome Patient Secondary to Terlipressin.
Topics: Cyanosis; Fatal Outcome; Female; Hepatorenal Syndrome; Humans; Ischemia; Middle Aged; Necrosis; Skin Diseases; Terlipressin; Vasoconstrictor Agents | 2019 |
Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis.
Topics: Aged; Albumins; Blood Pressure; Creatinine; Female; Heart Rate; Hepatorenal Syndrome; Humans; Kidney; Liver Failure; Lypressin; Male; Middle Aged; Prospective Studies; Sepsis; Terlipressin; Treatment Outcome | 2014 |
Severe ischemic bowel necrosis caused by terlipressin during treatment of hepatorenal syndrome.
Topics: Bilirubin; Creatinine; Electrocardiography; Fatal Outcome; Hepatorenal Syndrome; Humans; Intestinal Mucosa; Intestines; Liver Cirrhosis; Lypressin; Male; Middle Aged; Necrosis; Terlipressin; Tomography, X-Ray Computed; Vasoconstrictor Agents | 2013 |
Type-1 hepatorenal syndrome in patients with cirrhosis and infection vs. sepsis-induced acute kidney injury: what matters?
Topics: Albumins; Female; Hepatorenal Syndrome; Humans; Lypressin; Male; Sepsis; Terlipressin | 2014 |
Continuous outpatient terlipressin infusion for hepatorenal syndrome as a bridge to successful liver transplantation.
Topics: Hepatorenal Syndrome; Home Infusion Therapy; Humans; Infusions, Intravenous; Liver Transplantation; Lypressin; Male; Middle Aged; Terlipressin; Vasoconstrictor Agents | 2014 |
Transient increase in urine protein excretion during treatment with terlipressin and albumin for type-1 hepatorenal syndrome.
Topics: Albumins; Antihypertensive Agents; Biomarkers; Drug Therapy, Combination; Hepatorenal Syndrome; Humans; Lypressin; Terlipressin | 2015 |
Contrast-enhanced ultrasound evaluation of the renal microcirculation response to terlipressin in hepato-renal syndrome: a preliminary report.
Topics: Administration, Intravenous; Antihypertensive Agents; Hepatorenal Syndrome; Humans; Image Enhancement; Kidney Cortex; Lypressin; Male; Microcirculation; Middle Aged; Perfusion Imaging; Severity of Illness Index; Terlipressin; Treatment Outcome; Ultrasonography | 2015 |
Predictors of hepatorenal syndrome in alcoholic liver cirrhosis.
Topics: Acute Kidney Injury; Albumins; Analysis of Variance; Antihypertensive Agents; Female; Follow-Up Studies; Hepatorenal Syndrome; Humans; Liver Cirrhosis, Alcoholic; Lypressin; Male; Middle Aged; Risk Factors; Terlipressin | 2015 |
Hepatorenal syndrome after treatment of visceral leishmaniasis requiring terlipressin therapy.
Topics: Adult; Amphotericin B; Antiprotozoal Agents; Hepatorenal Syndrome; Humans; Leishmaniasis, Visceral; Lypressin; Male; Terlipressin; Vasoconstrictor Agents | 2015 |
Treatment of type 2 hepatorenal syndrome in patients awaiting transplantation: Effects on kidney function and transplantation outcomes.
Topics: Albumins; Creatinine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Glomerular Filtration Rate; Hepatorenal Syndrome; Humans; Injections, Intravenous; Kidney Function Tests; Liver Transplantation; Lypressin; Male; Middle Aged; Prospective Studies; Severity of Illness Index; Spain; Survival Rate; Terlipressin; Treatment Outcome; Vasoconstrictor Agents; Waiting Lists; Watchful Waiting | 2015 |
Efficacy of outpatient continuous terlipressin infusions for hepatorenal syndrome.
Topics: Hepatorenal Syndrome; Humans; Lypressin; Outpatients; Terlipressin; Vasoconstrictor Agents | 2016 |
Management of Hepatorenal Syndrome in the Era of Acute-on-Chronic Liver Failure: Terlipressin and Beyond.
Topics: Acute-On-Chronic Liver Failure; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Lypressin; Terlipressin; Vasoconstrictor Agents | 2016 |
Terlipressin, a vasoactive prodrug recommended in hepatorenal syndrome, is an agonist of human V1, V2 and V1B receptors: Implications for its safety profile.
Topics: Animals; Cell Line; CHO Cells; Cricetinae; Cricetulus; Cyclic AMP; Hepatorenal Syndrome; Humans; Inositol Phosphates; Liver Cirrhosis; Lypressin; Male; Prodrugs; Rats; Rats, Wistar; Receptors, Vasopressin; Terlipressin; Transfection; Vasopressins | 2016 |
Vasoconstrictor therapy for patients with cirrhosis with ascites but without hepatorenal syndrome.
Topics: Adrenergic alpha-Agonists; Ascites; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Lypressin; Midodrine; Terlipressin; Vasoconstrictor Agents | 2008 |
Terlipressin in 30 patients with hepatorenal syndrome: results of a retrospective study.
Topics: Adult; Aged; Creatinine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Liver Transplantation; Lypressin; Male; Middle Aged; Prognosis; Renal Dialysis; Retrospective Studies; Terlipressin; Vasoconstrictor Agents | 2009 |
Midodrine in the prevention of hepatorenal syndrome type 2 recurrence: a case-control study.
Topics: Case-Control Studies; Drug Administration Schedule; Female; Hepatorenal Syndrome; Humans; Lypressin; Male; Middle Aged; Midodrine; Prospective Studies; Secondary Prevention; Terlipressin; Treatment Outcome; Vasoconstrictor Agents | 2009 |
Terlipressin for hepatorenal syndrome: continuous infusion as an alternative to i.v. bolus administration.
Topics: Creatinine; Hepatorenal Syndrome; Humans; Infusions, Intravenous; Injections, Intravenous; Lypressin; Terlipressin; Vasoconstrictor Agents | 2009 |
Cutaneous necrosis secondary to terlipressin therapy.
Topics: Adult; Fatal Outcome; Hepatorenal Syndrome; Humans; Ischemia; Lypressin; Male; Necrosis; Skin; Terlipressin | 2009 |
Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome.
Topics: Aged; Albumins; Antihypertensive Agents; Blood Pressure; Creatinine; Female; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Lypressin; Male; Middle Aged; Predictive Value of Tests; Terlipressin | 2010 |
Terlipressin therapy for renal failure in cirrhosis.
Topics: Adult; Aged; Creatinine; Electrolytes; Female; Hemodynamics; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Lypressin; Male; Middle Aged; Multivariate Analysis; Renal Insufficiency; Retrospective Studies; Serum Albumin; Terlipressin; Treatment Outcome; Urea; Vasoconstrictor Agents; Young Adult | 2010 |
Targeting circulatory dysfunction in cirrhosis: terlipressin and the hepatorenal syndrome.
Topics: Hemodynamics; Hepatorenal Syndrome; Humans; Hypertension, Portal; Liver Circulation; Liver Cirrhosis; Lypressin; Renal Circulation; Terlipressin; Treatment Outcome; Vasoconstrictor Agents | 2009 |
Hepatorenal syndrome: diagnosis and effect of terlipressin therapy in 4 pediatric patients.
Topics: Adolescent; Child, Preschool; Female; Hepatorenal Syndrome; Humans; Infant; Lypressin; Male; Terlipressin; Treatment Outcome | 2010 |
Long-term treatment of hepatorenal syndrome as a bridge to liver transplantation.
Topics: Adult; Aged; Albumins; Creatinine; Drug Administration Schedule; Drug Therapy, Combination; Hepatorenal Syndrome; Humans; Liver Transplantation; Lypressin; Male; Middle Aged; Terlipressin; Time Factors; Vasoconstrictor Agents | 2011 |
[Type 2 hepatorenal syndrome in a cirrhotic patient who underwent gastric cancer surgery].
Topics: Adult; Hepatitis C; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Lypressin; Male; Portasystemic Shunt, Transjugular Intrahepatic; Stomach Neoplasms; Terlipressin; Tomography, X-Ray Computed; Vasoconstrictor Agents | 2010 |
Terlipressin infusion induces Tako-Tsubo syndrome in a cirrhotic man with hepato-renal syndrome.
Topics: Aged; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Lypressin; Male; Takotsubo Cardiomyopathy; Terlipressin | 2011 |
Continuous recurrence of type 1 hepatorenal syndrome and long-term treatment with terlipressin and albumin: a new exception to MELD score in the allocation system to liver transplantation?
Topics: Albumins; End Stage Liver Disease; Hepatorenal Syndrome; Humans; Liver Cirrhosis, Alcoholic; Liver Transplantation; Lypressin; Male; Middle Aged; Recurrence; Terlipressin; Time Factors; Treatment Outcome; Vasoconstrictor Agents | 2011 |
Pharmacological management of hepatorenal syndrome: lessons from non-responders.
Topics: Albumins; Creatinine; Female; Hepatorenal Syndrome; Humans; Lypressin; Male; Terlipressin | 2011 |
Diagnosis and therapy of ascites in liver cirrhosis.
Topics: Albumins; Ascites; Ascitic Fluid; Bacterial Infections; Clinical Trials as Topic; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Lypressin; Paracentesis; Peritonitis; Portasystemic Shunt, Transjugular Intrahepatic; Renin-Angiotensin System; Terlipressin | 2011 |
Terlipressin: an asset for hepatologists!
Topics: Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hepatorenal Syndrome; Humans; Lypressin; Male; Middle Aged; Terlipressin; Vasoconstrictor Agents | 2011 |
Treatment of the hepatorenal syndrome and hyponatremia in cirrhosis - part II.
Topics: Acute Kidney Injury; Clinical Protocols; Contraindications; Diuretics; Evidence-Based Medicine; Fluid Therapy; Hepatorenal Syndrome; Humans; Hyponatremia; Liver Cirrhosis; Lypressin; Renal Insufficiency, Chronic; Terlipressin; Vasoconstrictor Agents; Water-Electrolyte Imbalance | 2012 |
Outcomes of living donor liver transplantation for patients with preoperative type 1 hepatorenal syndrome and acute hepatic decompensation.
Topics: Adult; Albumins; Comorbidity; Female; Follow-Up Studies; Hepatorenal Syndrome; Humans; Immunosuppressive Agents; Liver Diseases; Liver Transplantation; Living Donors; Lypressin; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Renal Dialysis; Risk Factors; Terlipressin; Treatment Outcome | 2012 |
Hepatorenal syndrome: a severe, but treatable, cause of kidney failure in cirrhosis.
Topics: Albumins; Combined Modality Therapy; Follow-Up Studies; Hepatorenal Syndrome; Humans; Kidney Function Tests; Liver Cirrhosis; Liver Function Tests; Liver Transplantation; Lypressin; Male; Middle Aged; Renal Insufficiency; Risk Assessment; Severity of Illness Index; Terlipressin; Treatment Outcome | 2012 |
Terlipressin improves pulmonary pressures in cirrhotic patients with pulmonary hypertension and variceal bleeding or hepatorenal syndrome.
Topics: Antihypertensive Agents; Arterial Pressure; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Greece; Hepatorenal Syndrome; Humans; Hypertension, Pulmonary; Liver Cirrhosis; Lypressin; Male; Terlipressin; Treatment Outcome; Vascular Resistance; Vasoconstrictor Agents | 2012 |
Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis.
Topics: Adult; Female; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Lypressin; Male; Middle Aged; Predictive Value of Tests; Prognosis; Retrospective Studies; Severity of Illness Index; Survival Rate; Terlipressin; Vasoconstrictor Agents | 2002 |
Terlipressin-induced vasoconstriction reversed with N-acetylcysteine: a case for combined use in hepatorenal syndrome?
Topics: Acetylcysteine; Drug Therapy, Combination; Hepatorenal Syndrome; Humans; Lypressin; Terlipressin; Vasoconstriction; Vasoconstrictor Agents | 2002 |
Terlipressin and albumin for the hepatorenal syndrome.
Topics: Albumins; Drug Therapy, Combination; Hepatorenal Syndrome; Humans; Lypressin; Terlipressin; Vasoconstrictor Agents | 2003 |
Terlipressin plus hydroxyethyl starch infusion: an effective treatment for hepatorenal syndrome.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Drug Therapy, Combination; Hepatorenal Syndrome; Humans; Hydroxyethyl Starch Derivatives; Infusions, Intravenous; Lypressin; Male; Middle Aged; Plasma Substitutes; Postoperative Complications; Terlipressin; Vasoconstrictor Agents | 2003 |
Is spontaneous bacterial peritonitis an inducer of vasopressin analogue side-effects? A case report.
Topics: Aged; Ascites; Bacterial Infections; Dose-Response Relationship, Drug; Fatal Outcome; Gastrointestinal Hemorrhage; Hepatorenal Syndrome; Humans; Infusions, Intravenous; Ischemia; Liver Cirrhosis; Lypressin; Male; Peritonitis; Rectum; Serum Albumin; Terlipressin; Vasoconstrictor Agents | 2003 |
Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study.
Topics: Case-Control Studies; Female; Hepatorenal Syndrome; Humans; Kidney; Liver Failure; Liver Transplantation; Lypressin; Male; Middle Aged; Ornipressin; Postoperative Complications; Postoperative Period; Prognosis; Survival Analysis; Terlipressin; Treatment Outcome; Vasoconstrictor Agents; Vasopressins | 2004 |
Terlipressin and albumin combination treatment in hepatorenal syndrome.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Creatinine; Drug Therapy, Combination; Female; Hepatorenal Syndrome; Humans; Lypressin; Male; Middle Aged; Retrospective Studies; Survival Rate; Terlipressin; Turkey; Vasoconstrictor Agents | 2003 |
Terlipressin avoids hemodialysis in the treatment of refractory hyperkalemia associated with renal dysfunction in cirrhosis.
Topics: Hepatorenal Syndrome; Humans; Hyperkalemia; Liver Cirrhosis; Lypressin; Male; Middle Aged; Renal Agents; Terlipressin | 2005 |
[A case of peripheral ischemic complication after terlipressin therapy].
Topics: Adult; Hand; Hepatorenal Syndrome; Humans; Ischemia; Lypressin; Male; Terlipressin; Toes; Vasoconstrictor Agents | 2006 |
Long-term outcome of patients treated with terlipressin for types 1 and 2 hepatorenal syndrome.
Topics: Adult; Aged; Cardiovascular Agents; Female; Hepatorenal Syndrome; Humans; Kaplan-Meier Estimate; Kidney; Liver Transplantation; Lypressin; Male; Middle Aged; Patient Selection; Retrospective Studies; Risk Assessment; Severity of Illness Index; Terlipressin; Time Factors; Treatment Outcome | 2008 |
Pharmacological treatment of hepatorenal syndrome: a note of optimism.
Topics: Albumins; Baroreflex; Blood Pressure; Central Venous Pressure; Clinical Trials as Topic; Dose-Response Relationship, Drug; Hepatorenal Syndrome; Humans; Hypertension, Portal; Hypovolemia; Kidney; Lypressin; Norepinephrine; Portacaval Shunt, Surgical; Regional Blood Flow; Renal Artery; Terlipressin; Treatment Outcome; Vasoconstriction; Vasoconstrictor Agents | 2007 |
Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome.
Topics: Albumins; Female; Hepatorenal Syndrome; Humans; Kidney Function Tests; Liver Cirrhosis; Lypressin; Male; Middle Aged; Terlipressin; Time Factors; Vasoconstrictor Agents | 2008 |
Terlipressin infusion induces ischemia of breast skin in a cirrothic patient with hepatorenal syndrome.
Topics: Aged; Breast; Cyanosis; Female; Hepatorenal Syndrome; Humans; Infusions, Intra-Arterial; Ischemia; Liver Cirrhosis; Lypressin; Skin; Terlipressin; Vasoconstrictor Agents | 2008 |
[The results of treatment patients with hepatorenal syndrome. The analysis of 65 cases].
Topics: Adult; Albumins; Diuretics; Dopamine; Female; Hepatorenal Syndrome; Humans; Lypressin; Male; Middle Aged; Paracentesis; Renal Dialysis; Terlipressin; Treatment Outcome | 2006 |
Vasoconstrictor therapy for the hepatorenal syndrome.
Topics: Dose-Response Relationship, Drug; Hepatorenal Syndrome; Humans; Injections, Intravenous; Lypressin; Severity of Illness Index; Shock, Septic; Terlipressin; Treatment Outcome; Vasoconstrictor Agents | 2008 |
Hepatorenal syndrome. Long-term treatment with terlipressin as a bridge to liver transplantation.
Topics: Adult; Female; Hepatorenal Syndrome; Humans; Infusions, Intravenous; Liver Transplantation; Lypressin; Terlipressin; Time Factors; Vasoconstrictor Agents | 1996 |
Hepatorenal syndrome in cirrhotic patients: terlipressine is a safe and efficient treatment; propranolol and digitalic treatments: precipitating and preventing factors?
Topics: Adult; Aged; Digitoxin; Female; Hepatorenal Syndrome; Humans; Kidney Function Tests; Liver Cirrhosis, Alcoholic; Lypressin; Male; Middle Aged; Propranolol; Recurrence; Terlipressin; Vasoconstrictor Agents | 2000 |
Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study.
Topics: Aged; Antihypertensive Agents; Female; Follow-Up Studies; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Lypressin; Male; Middle Aged; Multivariate Analysis; Renal Insufficiency; Retrospective Studies; Survival Analysis; Terlipressin | 2002 |
Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study.
Topics: Aged; Creatinine; Female; Hemodynamics; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Liver Function Tests; Lypressin; Male; Middle Aged; Pilot Projects; Retrospective Studies; Terlipressin; Vasoconstrictor Agents | 2002 |